[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603087":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":15,"centralContacts":22,"locations":28,"responsibleParty":76,"collaborators":79,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":10,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":10,"enrollmentInfo":96,"targetDuration":10,"studyType":99,"phases":10,"briefSummary":100,"conditions":101,"keywords":106,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":119},{"fullName":5,"class":6},"University of Erlangen-Nürnberg Medical School","OTHER",[8,12],{"label":9,"type":10,"description":11,"interventionNames":10},"Primary brachytherapy",null,"Patients receiving sole primary brachytherapy (either LDR-BT or HDR-BT) for low or low intermediate risk prostate cancer",{"label":13,"type":10,"description":14,"interventionNames":10},"Salvage brachytherapy","Patients receiving sole brachytherapy (either PDR-BT or HDR-BT) for locally recurrent prostate cancer after prior irradiation with prostate in situ",[16,20],{"name":17,"affiliation":18,"role":19},"Claudia Schweizer, MD","Strahlenklinik Universitätsklinikum Erlangen","PRINCIPAL_INVESTIGATOR",{"name":21,"affiliation":18,"role":19},"Anna-Jasmina Donaubauer, Dr. rer. nat.",[23,27],{"name":17,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","+49 9131 85 33968","claudia.schweizer@uk-erlangen.de",{"name":21,"role":24,"phone":10,"phoneExt":10,"email":10},[29,48,63],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Klinik für Strahlentherapie","NOT_YET_RECRUITING","Augsburg","Bavaria","86156","Germany","DE",{"type":38,"coordinates":39},"Point",[40,41],10.89851,48.37154,{"lat":41,"lon":40},[44],{"name":45,"role":24,"phone":46,"phoneExt":10,"email":47},"Klinik für Strahlentherapie Augsburg","+49 821 400-2080","strahlenklinik@uk-augsburg.de",{"facility":49,"status":50,"city":51,"state":33,"zip":52,"country":35,"countryCode":36,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Strahlenklinik Erlangen","RECRUITING","Erlangen","91054",{"type":38,"coordinates":54},[55,56],11.00783,49.59099,{"lat":56,"lon":55},[59],{"name":60,"role":24,"phone":61,"phoneExt":10,"email":62},"Strahlenklinik Erlangen Ambulanz","+4991318534080","sekretariat.strahlenklinik@uk-erlangen.de",{"facility":64,"status":31,"city":65,"state":33,"zip":66,"country":35,"countryCode":36,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Klinik und Poliklinik für Strahlentherapie und Radioonkologie","Munich","81377",{"type":38,"coordinates":68},[69,70],11.57549,48.13743,{"lat":70,"lon":69},[73],{"name":64,"role":24,"phone":74,"phoneExt":10,"email":75},"+49 (0)89 \u002F 4400 - 73770","strahl.onlinetermine@med.uni-muenchen.de",{"type":19,"investigatorFullName":77,"investigatorTitle":78,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Claudia Schweizer","Claudia Schweizer MD",[80,83,85],{"name":81,"class":82},"Bavarian Cancer Research Center (BZKF)","UNKNOWN",{"name":84,"class":6},"University Hospital Augsburg",{"name":86,"class":6},"Ludwig-Maximilians - University of Munich","100603087","immune-biomarkers-in-prostate-cancer-patients-treated-with-brachytherapy-100603087",false,"NCT07131956","Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy","Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy (ImmunBioProBrachy)","Inclusion Criteria Arm 1:\n\n* Primary treatment with I-125 seeds or HDR-BT\n* No previous treatment for prostate cancer\n* Age ≥ 18 years\n\nInclusion Criteria Arm 2:\n\n* HDR- or PDR-BT\n* No radiation therapy within three months before salvage treatment\n* Complete documentation available on previous treatment for prostate cancer\n* No history of prostatectomy\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Pre-existent auto-immune disease\n* patients under bloodthinning medication\n* substance abuse","MALE","18 Years",{"count":97,"type":98},200,"ESTIMATED","OBSERVATIONAL","Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.",[102,103,104,105],"Prostate Cancer (Diagnosis)","Prostate Cancer Patients Who Have Brachytherapy Seed Implant","Prostate Cancer Patients Treated by Radiotherapy","Prostate Cancer Recurrent",[107,108,109],"Immune-profiling in prostate cancer patients","brachytherapy for prostate cancer","interstitial brachytherapy for prostate cancer","2025-11-17",{"date":112,"type":113},"2025-11-18","ACTUAL",{"date":115,"type":98},"2025-12",{"date":117,"type":98},"2028-07-31",{"name":5,"class":6},3]